Among young adults (18–40 years old) transplanted for MDS who were enrolled in the Center for International Blood and Marrow Transplant Research (CIBMTR) repository between 2005 and 14, 4% were discovered to have germline compound heterozygous mutations in the SBDS gene (Lindsley et al., 2017) with concurrent somatic biallelic loss-of-function TP53 variants. The gene discussed is TP53; the disease is myelodysplastic syndrome.